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Disclaimers
The information contained in this document does not constitute legal advice. Use of any provision 
herein should be contemplated only in conjunction with advice from legal counsel. Provisions may 
need to be modified, supplemented, or replaced to ensure appropriate citation to or compliance 
with relevant local and state laws, to accurately reflect the intent of parties to a particular 
agreement, or to otherwise address the needs or requirement of a specific jurisdiction. 
Web site addresses of nonfederal organizations are provided solely as a service to readers. 
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Purpose  
The purpose of this document is to provide the Centers for Disease Control and Prevention’s (CDC) 
DP15-1502 grantees with Colorectal Cancer Control Program (CRCCP) guidance for measuring baseline 
and, thereafter, annual colorectal cancer (CRC) screening rates within participating health system clinics. 
Reporting Requirements 
CDC has awarded DP15-1502 grants to increase CRC screening rates (priority outcome) among a defined 
target population within a partner health system, defined geographical area, or disparate population. 
Grantees implement evidence-based interventions (EBIs) and other (optional) supportive strategies in 
partnership with health systems to put into place organized screening programs (see Figure). In 
addition, CRCCP grantees measure and report a baseline screening rate for health systems where 
implementation is planned, followed by an annual screening rate report. 
A health system partner may include federally qualified health centers (FQHCs), community health 
centers (CHCs), health care or hospital networks, Indian Health Service (IHS) and local health 
department clinics, among others. Health systems often have multiple clinics (FQHCs refer to them as 
sites). Because grantees may intervene with only a subset of these clinics and may have different 
activities in different clinics, it is important to measure and report a baseline CRC screening rate for 
every clinic within a health system, rather than for the overall health system, where CRCCP activities are 
implemented (see Figure). The clinic-level CRC screening rate is updated annually thereafter. These data 
will allow grantees and CDC to monitor trends in CRC screening rates in all clinics where program 
activities are implemented and allow better evidence of the impact of the CRCCP.  
Figure.  CRCCP Grantee, Health System, Clinic Sites 
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Selecting a CRC Screening Rate Measure and Using It Consistently 
This section describes the importance of selecting a specific measure or method to calculate the 
screening rate at baseline and then using that same measure or method consistently throughout the 
DP15-1502 reporting period. The two options for reporting CRC screening rates are (1) using an existing 
measure (e.g., Uniform Data System [UDS]) or (2) calculating a new rate based on the National Quality 
Forum (NQF)-endorsed measure. As part of initial assessment efforts conducted with a partner health 
system, identify the option most appropriate for each clinic where CRCCP program activities are 
planned. 
Selecting a CRC Screening Rate Measure 
Several performance measures exist to monitor CRC screening rates within a health system or clinic. The 
table at the end of this document provides a comprehensive overview of these measures. If a health 
system clinic already reports one of these measures (e.g., UDS), then that measure may be reported to 
CDC. This is intended to facilitate partnership development and build on the existing health system or 
clinic structure. However, CDC encourages grantees to work closely with partners to improve reporting 
quality, particularly if there is evidence of imprecision or inconsistency in CRC screening rate reporting 
(see EHR validation on page 5).
When using an existing CRC screening rate measure such as UDS for a given clinic, report the measure 
for the same 12-month time period as was reported to the external system. Follow the same guidelines 
recommended for calculating that measure (see Table on page 9). For example, if a grantee is partnering 
with a FQHC that has six individual clinic sites and is implementing program activities in four of them, 
report the UDS screening rates to CDC for the time period January—December for each of the four 
clinics. If a single, aggregate screening rate for the entire health system (representing all six clinics) was 
reported by the FQHC to HRSA, the clinic-level rate for each of the four clinics must be provided to 
CDC. Again, report the values representing the same 12-month measurement year that was used to 
report to HRSA. Do not report a number that has been updated to represent a different or longer 
measurement year. Important Note: In CDC’s data collection, grantees will report both the numerator 
and denominator population sizes (raw data) at baseline and annually.
Baseline Time Period 
Grantees need to determine a baseline CRC screening rate for each participating clinic before 
implementing CRCCP program activities. Specifically, the baseline measurement year needs to represent 
the most recent 12-month measurement year that precedes intervention activities. For example, if a 
grantee begins implementing program activities in a given FQHC clinic in November 2015, a baseline 
screening rate (e.g., UDS) for the time period January 2014—December 2014 is reported. Once baseline 
clinic data are collected and reported, track the month that CRCCP activities are implemented in each 
clinic. This information is provided to CDC as part of your annual clinic data reporting and will aid future 
analysis to assess the effects of the CRCCP.  
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Reporting an Annual Screening Rate 
Once a baseline screening rate is reported for a given clinic, provide CDC an annual screening rate for 
that clinic through the end of the 5-year program period, regardless of whether the program remains 
actively engaged in implementing program activities for that entire period. For instance, a clinic in 
program year 1 may be identified, and, based on assessment activities, may put into place patient and 
provider reminder systems along with using small media over a 3-year period to improve screening 
rates. In this scenario, a baseline screening rate for the clinic before implementing activities would be 
reported followed by an annual screening rate for all 5 years. This will allow grantees and CDC to assess 
the full effect of the EBIs that were implemented over the program period. 
Note: CDC is requiring that grantees report screening rates annually. However, grantees may choose to 
monitor these rates more frequently.  
Measuring Consistently 
Grantees may use different CRC screening measures for different clinics (e.g., UDS for Clinic 1, 
government performance and results act [GPRA] for Clinic 2). However, after selecting the most 
appropriate measure for a given clinic, use that same measure (and calculation) and the same 12-
month measurement year for reporting in all subsequent years. For example, if the UDS CRC screening 
measure is used as the baseline screening rate for Clinic 1 for the 2015 calendar year (January 1, 2015–
December 31, 2015), the UDS CRC screening measure needs to be reported for that clinic for all 
subsequent years (calendar years 2016, 2017, 2018, etc.). The 12-month measurement year for the 
screening measure does not need to match the CRCCP program year. 
Calculating NQF-Endorsed CRC Screening Rate Measure 
As of December 2014, the NQF-endorsed measure is the National Committee for Quality Assurance 
(NCQA) measure for CRC screening (i.e., HEDIS measure).1 If a grantee’s partner health system or clinic 
does not currently report an existing CRC screening measure, or prefers to use a measure different from 
what is normally reported, CDC recommends that grantees follow the NQF’s endorsed measure 
definition. Please follow the guidance below to calculate this measure.  
Step 1. Determining the Measurement Year 
The NQF-endorsed measure uses the calendar year as the measurement year (January 1—December 
31).  
Step 2. The NQF-Endorsed CRC Screening Rate Measure Definition 
The NQF describes the CRC screening rate measure as the percentage of patients 50–75 years of age 
who are up-to-date with appropriate screening for colorectal cancer. The screening rate needs to be 
calculated using the numerator and denominator definitions described below. As a reminder, both the 
numerator and denominator population sizes, not just the screening rate, need to be reported to CDC at 
baseline and annually. 
1 For more information regarding NQF (including background information, measure definitions, and relevant CPT 
codes) visit www.qualityforum.org/Measures_Reports_Tools.aspx. 
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Step 3. Defining the Denominator  
The denominator is the number of patients aged 51–752 years with a medical visit during the 
measurement year. 
NOTE: Exclusionary criteria 
Exclude patients with a diagnosis of colorectal cancer or total colectomy from the calculation. 
Step 4. Defining the Numerator 
The numerator is the number of patients aged 51–75 years with 1 or more appropriate screenings for 
colorectal cancer, who had at least 1 medical visit during the measurement year. 
What Is Appropriate CRC Screening? 
Appropriate screening is defined as having any of the following CRC screening tests: 
• Fecal occult blood test (FOBT), including fecal immunochemical test (FIT), during the
measurement year.
• Flexible sigmoidoscopy during the measurement year or the 4 years before the measurement
year.
• Colonoscopy during the measurement year or the 9 years before the measurement year.
Measurement Considerations for FOBT/FIT 
To qualify as receiving appropriate screening, sufficient evidence of a test kit receipt and lab processing 
is needed. Evidence solely of mailing a FOBT/FIT kit to a patient or use of in-office obtained stool 
specimens (i.e., digital rectal exam) are insufficient. As an additional quality consideration, adhere to the 
quality criteria for a given kit type regarding the number of fecal samples required. Information available 
in the patient medical chart, including patient-reported screening history, represents adequate evidence 
of appropriate screening as long as a test date is recorded in the medical record or chart. 
Measurement Considerations When Using Electronic Health Records (EHRs)  
Health system use of EHRs is increasing. A functional EHR system, especially in clinics with large patient 
populations, is integral to building an organized screening system. EHRs may represent a potential 
source of data for calculating CRC screening rates. The accuracy of data extracted from EHRs can vary for 
many reasons, including how data are documented and entered into the EHR. Grantees are encouraged 
to work with partner health systems to improve the accuracy of EHR-generated CRC screening rates and 
improve its functional use.  
2Although the measure definition encompasses ages 50–75, the actual calculation covers patients ages 51–75 to 
allow people to be screened within a year of turning 50 and before reaching the age of 75. For example, if a 
grantee’s 12-month measurement year runs from January 1, 2015—December 31, 2015, only patients with a date 
of birth between January 1, 1941, and December 31, 1964, are included in the calculation. 
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The National Colorectal Cancer Roundtable’s (NCCRT) summary report, Use of Electronic Medical 
Records to Facilitate Colorectal Cancer Screening in Community Health Centers3 documents several other 
potential problems that could lead to calculating an inaccurate CRC screening rate using EHRs. Potential 
problems may include a system not optimized for easy CRC screening tracking, poor documentation of 
previous screening received outside of the health system, lack of ongoing training for staff, and family 
history data not easily accessible. Refer to this guide for additional information that may help to 
diminish the effect of these problems on extracting data from EHRs.  
Assess the quality of the EHR system to determine whether it can be used to calculate a CRC screening 
rate for reporting to CDC. CDC suggests that the EHR system adhere to the following criteria: 
• Length of time the EHR has been operational. Preferably, an EHR system needs to be fully
operational for at least 2 calendar years (or data for this time period must be imported into
the system). If this criterion is not met, conducting a medical chart review is recommended
as an alternative to calculate a CRC screening rate.
• Format of data. The EHR system needs to have the functionality to identify all CRC screening
tests performed in the clinic or by other providers within a specified timeframe. For
instance, assess whether data are input into a specific data field or fields or if CRC screening
test results have been scanned into the EHR. Also, determine whether the data fields being
used are used consistently across providers. The EHR must be able to be effectively queried
and accurate data extracted from these fields.
• Identify exclusions. The EHR system needs to allow for exclusions as part of a query (e.g.,
patients who have had colorectal cancer or a colectomy).
• Comprehensive collection. The EHR system needs to be able to identify CRC screening data
from prior years in order to determine if patients meet standards of being up-to-date with
appropriate screening.
Validating the EHR Rate  
Validation is an important step in determining the accuracy of the EHR-generated screening rate. Given 
the EHR issues described above, EHR-generated screening rates may be underreporting the actual 
screening rate. To validate the accuracy of an EHR-generated CRC screening rate, we recommend 
comparisons with a screening rate calculated via medical chart review. This type of validation is 
especially beneficial for EHR systems that have been in place for a short amount of time (less than 2 
years) or have not been able to meet the criteria previously detailed. EHR validation is an ongoing 
process, not a one-time event. Validation may require multiple iterations to achieve accuracy in the 
EHR-generated CRC screening rate. Thus, the process of validating a clinic’s EHR system may overlap 
with the implementation of EBIs and supportive activities. If discrepancies between the EHR rate and the 
chart review rate exist, grantees may choose to report medical chart review results to CDC. Validation 
results can subsequently be used to make improvements or enhancements to the EHR system. Once the 
3 National Colorectal Cancer Roundtable, American Cancer Society, and National Association of Community Health 
Centers. Use of Electronic Medical Records to Facilitate Colorectal Cancer Screening in Community Health Centers. 
Access report at http://nccrt.org/about/disparities/report-on-use-of-electronic-medical-records-to-facilitate-
colorectal-cancer-screening-in-community-health-centers/.  
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EHR has been improved or enhanced and the system is able to produce an accurate CRC screening rate, 
it can be used for reporting to CDC.  
Using Medical Chart Review to Estimate a CRC Screening Rate 
Guidance for conducting a medical chart review or abstraction is detailed below. This process can also 
be followed when conducting medical chart reviews to validate an EHR. For more specific information 
and tools (including Chart Audit Sample Templates), refer to the NCCRT’s manual Steps for Increasing 
Colorectal Cancer Screening Rates: A Manual for Community Health Centers. While this manual is set in 
the context of community health centers, information related to sampling methods and tracking chart 
audits can be applied to other types of health systems. 
Proportion of Medical Charts to Review 
To ensure an accurate CRC screening rate, determine the appropriate number of charts to review before 
initiating the medical chart review process. Many statistically rigorous approaches can be used, such as 
specifying the confidence level and measurement of error based on the clinic population size. Apply 
these approaches if the necessary capacity exists or there is access to staff with statistical expertise. If 
those resources are unavailable, then, at a minimum, conduct a review of 10% of the medical charts for 
adults meeting the denominator definition for the measure used (e.g., for UDS, 10% of charts for adults 
aged 51–74, who had at least 1 medical visit during the measurement year). If the clinic population for 
that group (e.g., adults aged 51–74) exceeds 1,000 patients, then the sample can be limited to 100 
patients. Because CDC requires reporting of clinic-level screening rates, draw a sample from each clinic 
where CRCCP intervention activities are planned or implemented. The number of charts reviewed will be 
used as the denominator for screening rate calculations. Note: Remember to oversample (i.e., pull more 
medical charts than the number initially identified) in order to account for patients who need to be 
excluded from the denominator (i.e., those patients with a previous diagnosis of CRC or total 
colectomy). 
Selecting Appropriate Charts 
This section describes the process for selecting medical charts that will be used to draw a sample. The 
selection process includes determining the appropriate population, identifying the number to sample, 
conducting a random or systematic sample, identifying available data sources, or replacing excluded 
patients.   
Determine the Sampling Frame 
The sampling frame includes all patients in the clinic population for which it is appropriate to sample. 
The sampling frame provides the larger patient population list from which samples will be pulled. 
Inclusion criteria must be identified before generating the list of patients. One important criterion is that 
the sampling frame must include all patients who had at least 1 medical visit during the 12-month 
measurement year. Additional criteria can be added as appropriate (e.g., the sampling frame must 
include patients who received contracted medical services during the 12-month measurement year). A 
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patient initially listed in the sampling frame may need to be removed if, upon further inspection, he or 
she was included by mistake or does not meet the predetermined inclusion criteria.  
Sampling Method 
After determining the appropriate population to sample (sampling frame), select a sampling method 
that will generate a representative sample of the entire population of patients who meet the selection 
criteria. Random sampling or systematic sampling are two recommended options. A random sample 
takes a randomly assigned subset of the population identified in the sampling frame. This is typically 
accomplished through generating a random number that will be assigned to each patient in the 
sampling frame. This can be accomplished in many ways (e.g., random number table, Web application, 
or computer software such as Microsoft Excel).  
A systematic sample orders every patient (i.e., alphabetically, by ID) in the sampling frame and then 
selects every nth patient. A general rule is to take the number of patients in the sampling frame and 
divide by the number of patients needed in the sample to determine the best interval. For example, if a 
clinic contains 800 patients in the sampling frame and needs to include 10% (or 80 patients) in the 
sample, divide 800 by 80 and select every 10th patient. A small percentage (1%–5%) of patients may 
need to be selected to use as a replacement; for example, if those patients initially selected do not meet 
criteria or they meet some exclusion criteria. 
Measurement Year 
The defined 12-month measurement year is used as the basis for the medical chart abstraction. Do not 
extract data prior to the end of the measurement year because this could exclude patients who are 
screened toward the end of the measurement year. We recommend conducting the abstraction within 2 
months after the end of the measurement year. For example, if the measurement year runs from 
January 1, 2015 to December 31, 2015, complete chart reviews between January 1, 2016, and March 1, 
2016. 
Additional Considerations 
Assessing Data Reliability  
No one method for abstracting data is perfect. CDC anticipates limitations and challenges in calculating a 
screening rate regardless of the method used (medical chart abstraction, EHR-generated rate). We also 
anticipate that CRC screening rate estimates may improve over time as a health system’s EHR improves 
or chart abstraction methods are strengthened. Consequently, when calculating a CRC screening rate, it 
will be beneficial to assess the perceived reliability of the data reported. Identifying and documenting 
potential issues with the collection or extraction of CRC screening rate data will provide important 
context to changes in these rates over time. Additionally, CDC will ask grantees to report on the 
reliability of the screening rate data reported. 
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Tools and Resources 
The following list of resources (many of which are referenced in this document) may be helpful when 
collaborating with health system partners and clinics: 
• National Colorectal Cancer Roundtable and American Cancer Society. Steps for Increasing
Colorectal Cancer Screening Rates: A Manual for Community Health Centers.
http://nccrt.org/about/provider-education/manual-for-community-health-centers-2/.
• National Colorectal Cancer Roundtable, American Cancer Society, and National Association
of Community Health Centers. Use of Electronic Medical Records to Facilitate Colorectal
Cancer Screening in Community Health Centers. http://nccrt.org/about/disparities/report-
on-use-of-electronic-medical-records-to-facilitate-colorectal-cancer-screening-in-
community-health-centers/.
• Centers for Disease Control and Prevention. Increasing Colorectal Cancer Screening: An
Action Guide for Working with Health Systems. https://www.cdc.gov/cancer/crccp/action-
guides.htm.
Sources 
Information in this document was informed by the following sources: 
• DP15-1502 FOA: Organized Approaches to Increasing Cancer Screening.
• National Colorectal Cancer Roundtable, American Cancer Society, and National Association of
Community Health Centers report: Use of Electronic Medical Records to Facilitate Colorectal
Cancer Screening in Community Health Centers.
• American Cancer Society and National Colorectal Cancer Roundtable’s manual: Steps for
Increasing Colorectal Cancer Rates: A Manual for Community Health Centers.
• National Quality Forum’s (NQF) Quality Positioning System.
• NCQA’s Healthcare Effectiveness Data and Information Set (HEDIS) 2015 Performance
Measurement Specifications.
• HRSA’s Uniform Data System (UDS) 2014 manual: Reporting Instructions for Health Centers.
• IHS’ Clinical Reporting System’s 2013 National GPRA Developmental Report.
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Table. Colorectal Cancer Screening Rate Measures 
Measure Reporting  
Period 







Proportion of clinically 
appropriate patients 50 
through 75 years of age 
who have received 
colorectal screening. 
Patients who have 
had ANY CRC 
screening. 
Active clinical patients 50–75 
years of age without a 
documented history of 
colorectal cancer or total 
colectomy. 
Fecal occult blood test (FOBT) or fecal 
immunochemical test (FIT) during report 
period, flexible sigmoidoscopy in past 5 














Percentage of adults 
50–75 years of age who 
had appropriate 
screening for colorectal 
cancer. 
Patients in the 
denominator who 




All patients 51–75 years of age 
during the measurement year.  
Exclusions: Colorectal cancer, 
total colectomy. 
Guaiac or immunochemical (FIT) FOBT 
during the measurement year, flexible 
sigmoidoscopy during the measurement 
year or the 4 years before the measurement 
year, FIT-DNA test during the measurement 
year or the 2 years before the measurement 
year, CT colonography during the 
measurement year or the 4 years before the 
measurement year or colonoscopy during 
the measurement year or the 9 years before 












Percentage of patients 
50–75 years of age who 
had appropriate 
screening for colorectal 
cancer. 
Number of active 
patients 51–74 





Number of patients who were 
51–74 years of age at some 
point during the measurement 
year, who had at least 1 medical 
visit during the reporting year. 
Exclusions: Have or have had 
colorectal cancer. 
Guaiac-based FOBT, or FIT, during the 
measurement year, flexible sigmoidoscopy 
during measurement year or previous 4 
years, or colonoscopy during measurement 










Percentage of adults 
50–75 years of age who 
had appropriate 




years of age with 
1 or more 
screenings for 
colorectal cancer. 
Number of patients 51–75 years 
of age with a visit during the 
measurement year. 
Exclusions: Colorectal cancer, 
total colectomy 
FOBT—including FIT—during the 
measurement year, flexible sigmoidoscopy 
during the measurement year or the 4 years 
prior to the measurement year, or 
colonoscopy during the measurement year 
or the nine years before the measurement 
year. 
a National Committee for Quality Assurance (NCQA) bHealth Resources and Services Administration (HRSA) 
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